Spondyloarthritis & psoriatic arthritis
Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study
Main findingResult — go to the resultAdjusted odds ratio 1.157 95% CI 0.734–1.825Authors' conclusion
TNFi exposure was not associated with an increased risk of cancer recurrence in patients with AS.
Study context
- Population
- Patients with AS and a history of cancer after AS diagnosis, nationwide databasecohort
- Participants
- 2,574 patients
- Comparison
- Cancer recurrence cases vs matched controls: Tumour necrosis factor inhibitors (TNFi) exposure
- Casesn = 254
- Controlsn = 254reference
- Outcome
- Cancer recurrence associated with TNFi exposure
Methodological detailsnationwide database, controls matched 1:1 for age, sex, date of index cancer diagnosis and follow-up time, multivariable conditional logistic regression
- Nationwide database
- Controls matched 1:1 for age, sex, date of index cancer diagnosis and follow-up time
- Multivariable conditional logistic regression
Main finding
As reported in the abstract
Adjusted odds ratio
1.157
95% CI 0.734–1.825
P = 0.531
By group
TNFi exposurevs No TNFi exposure
aOR 1.157 (95% CI 0.734–1.825); P = 0.531
Observational data: associations, not effects.
Further findings
Cancer recurrence in the cohort
- Cancer recurred
- 394 (15.3%)
- Incidence rate of cancer recurrence, /100 person-years
- 4.87 (95% CI 4.40-5.34)
Original publication
Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study. Rheumatology (Oxford). Published 6 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →